ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2663

Sense of Smell, Anti-Ribosomal P Antibodies and Neuropsychiatric Manifestations in Systemic Lupus Erythematosus

Fernando Augusto Peres1, Karina Oliveira Peliçari2, Nailu A. Sinicato1, Mariana Postal1, Aline T. Lapa1, Lilian Costallat3 and Simone Appenzeller4, 1Medicine, State University of Campinas, Campinas, Brazil, 2State University of Campinas, Campinas, Brazil, 3Medicine, State University of Campinas, Campinas, United Kingdom, 4Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Antibodies, neurologic involvement and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Epidemiology, Women's Health, Cardiovascular and CNS

Session Type: Abstract Submissions (ACR)

Background/Purpose Neuropsychiatric manifestations occur in 12-95% of SLE patients. Recent studies have demonstrated the high specificity of antiribosomal P antibodies for SLE. Antiribosomal P antibodies are able to bind to neuronal cells in areas of the limbic system which are responsible to the olfactory. We aimed to analyze the prevalence of olfactory disorder in SLE, correlate olfactory with presence of neuropsychiatric manifestations, disease activity and the presence of antiribosomal P antibodies.

Methods Consecutive SLE patients followed at the rheumatology unit of the State University of Campinas were enrolled in this study. The control group was consisted by age and sex matched healthy individuals. A complete clinical, laboratory and neurological evaluation was performed in all subjects. Neurological manifestations were analyzed according to the ACR classification criteria. Mood and anxiety disorders were determined through Becks Depression and Becks Anxiety Inventory. SLE patients were further assessed for clinical and laboratory SLE manifestations, disease activity [SLE Disease Activity Index (SLEDAI)], damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index). Anti-ribosomal P antibody was performed by Enzyme Linked Immuno Sorbent Assay. Olfactory functions were evaluated using the Sniffin’ Sticks test, in 3 stages: threshold, discrimination, and identification of different odors (TDI).

Results We included 120 SLE patients (93.3% female; mean age 40.3 years; SD±11.3 years) and 135 healthy volunteers (91.1% female; mean age 37.6 years; SD±12.4 years). Anxiety was observed in 81(67.5%) SLE patients and in 49 (39.2%) controls (p<0.001). Depression was identified in 56 (46.6%) SLE patients and in 39 (28.8%) controls (p=0.004). Anti-ribosomal P antibodies were identified exclusively in SLE patients and were present in 13 (10.8%) of them (p<0.001). Olfactory changes were observed in 62 (51.6%) SLE patients and in 40 (29.6%) controls (p=0.001). SLE patients had significantly lower mean in all phases of the olfactory assessment. The olfactory was also inversely associated with anxiety (p=0.004, R=-0.18), depression (p=0.01, R =-0.232), cumulative damage (p=0.002, R =-0.282) and age (p<0.001, R=-0.353). The TDI was correlated with a CNS involvement, and patients with NP manifestations [mean of 28.35 (SD ± 5.30)] points, whereas patients without NP manifestations had a mean TDI of 30.8 (SD ± 4.51) points (p<0.001). Antiribosomal P antibodies were not associated with CNS involvement (p=0.730), but when we analyzed each manifestation separately, we observed an association between the presence of antiribosomal P antibodies and psychosis (p<0.046). We also observed an association between antiribosomal P antibodies and disease activity (p=0.036).

Conclusion SLE patients have a significant decrease of smell when compared to healthy controls. Olfactory changes are associated with a history of neuropsychiatric symptoms, anxiety, depression, cumulative damage, and age. Antiribosomal P antibodies were exclusively observed in SLE patients compared to healthy controls and they were associated with psychosis and disease activity.


Disclosure:

F. A. Peres,
None;

K. O. Peliçari,
None;

N. A. Sinicato,
None;

M. Postal,
None;

A. T. Lapa,
None;

L. Costallat,
None;

S. Appenzeller,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sense-of-smell-anti-ribosomal-p-antibodies-and-neuropsychiatric-manifestations-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology